Probiotic–Nanocurcumin Combination Therapy: A Novel Strategy for Colorectal Cancer

Abstract

Colorectal cancer (CRC) remains one of the leading causes of cancerrelated morbidity and mortality worldwide. The growing body of evidence suggests that gut microbiota plays a critical role in CRC development and progression, thereby opening avenues for novel therapeutic strategies. Probiotics and curcumin have separately demonstrated beneficial effects in cancer prevention and treatment, but their combined potential remains underexplored. This paper explores the synergistic effects of probiotic–nanocurcumin combination therapy in CRC treatment. Probiotics, through modulation of the gut microbiome, enhance immune function and reduce inflammation, while nanocurcumin, a nanoparticle-based formulation of curcumin, improves the bioavailability and targeted delivery of curcumin to cancerous tissues. The combination of these therapies may offer a multi-targeted approach, reducing the side effects of traditional therapies, enhancing therapeutic outcomes, and promoting gut health. This review critically examines the underlying mechanisms of action, preclinical and clinical studies, and potential applications of probiotic–nanocurcumin therapy as a novel and effective adjunct in colorectal cancer management. Future research directions and clinical trials will be essential to validate the therapeutic potential of this combination approach.